Striverdi Respimat
(Olodaterol)ApprovedSmall molecule
Boehringer IngelheimStriverdi Respimat is a small molecule that works as a Beta-2 Adrenergic Receptor Agonist.[2] It is being used across 5 indications, with its most advanced program in Approved.[1]
Striverdi Respimat is one of 149 small molecule programs targeting Airway obstruction. It is currently in Approved.
5
Indications
36
Total Trials
0
Active Trials
148
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
161 competitors in Asthma
#DrugCompanyPhaseTrials
1Striverdi Respimat
Boehringer IngelheimApproved
Arcoxia
NovartisPreclinical
Blood Withdrawn
Emergent BioSolutionsPreclinical
Aclidinium Bromide
AstraZenecaPreclinical
Ozone
TTanta University
Preclinical
Lexapro
SShirley Ryan AbilityLab
Preclinical
Biological Drug
UUniversitaire Ziekenhuizen KU Leuven
Preclinical
Guanidine Hydrochloride
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Rhinovirus
UUniversity of Virginia
Preclinical
FP/SAL
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Obstructive Pulmonary Disease12 trials
Show 9 more trials
COPD5 trials
Asthma5 trials
Exercise2 trials
8 more indications
Salmeterol1 trial
Physical Activity1 trial
Function1 trial
Corticosteroids1 trial
COPD (Chronic Obstructive Pulmonary Disease)1 trial
Regulatory
FDA Approval Timeline[4]
Jul 31, 2014
STRIVERDI RESPIMAT
NDA NDA203108
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Olodaterol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Beta-2 Adrenergic Receptor Agonist[2]
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company